Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study

Table 5 Comparison of the two treatment groups for osteoarthritis

Item		BGP	IL-17	S100A12	SIP	Cysc	SCr	Hb
Eucommia and meloxicam group	Before treatment	2.12 ± 0.12	152 ± 6.13	43 ± 3.2	0.23 ± 0.05	0.83 ± 0.3	46 ± 4.2	132 ± 8.9
	After treatment	1.88 ± 0.35	136.44 ± 4.58	36.37 ± 5.68	0.116 ± 0.05	1.12 ± 0.5	63 ± 3.6	113 ± 12.1
	t	2.228	6.4	4.008	6.334	3.894	10.17	2.55
	P	0.053	0.000	0.003	0.000	0.004	0.000	0.031
Meloxicam group	Before treatment	0.87 ± 0.21	125 ± 6.4	32 ± 6.3	0.11 ± 0.05	0.87 ± 0.43	53 ± 4.9	124 ± 3.6
	After treatment	0.64 ± 0.19	104 ± 6.4	18 ± 3.4	0.057 ± 0.01	1.46 ± 0.42	74 ± 5.7	104.3 ± 6.8
	t	3.915	7.848	5.609	5.331	3.155	15.374	10.632
	P	0.004	0.000	0.000	0.000	0.012	0.000	0.000
Comparison of the two groups before treatment	t	30.644	12.747	5.827	6.357	3.399	7.23	2.215
	P	0.000	0.000	0.000	0.000	0.008	0.000	0.054
Comparing the two groups after treatment	t	35.845	14.523	8.409	3.174	2.774	4.97	2.456
	P	0.000	0.000	0.000	0.011	0.022	0.000	0.036

BGP: Bone-GLA protein; S100A12: Recombinant human S100 calcium binding protein A12; SIP: Sphingosine 1-phosphate; Cysc: Cystatin C; SCr: Creatinine; Hb: Hemoglobin.